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ABSTRACT: Cutaneous ulcerations may be due to a variety ol
causes, including vasculitis, infections, arterial insufficiency,
and microvascular damage. The net effect is diminished blood
flow to the skin. Nifedipine, a calcium antagonist, has been
shown to improve cutaneous blood (low and to alleviate reac-
tive vasospastic ischemia (Raynaud's phenomenon). The au-
thors report an ischemic ulcer of scleroderma showing visible
improvement with nifedipine therapy.
Progressive systemic scleroderma (PSS) is a debilitat-
ing disorder with a multitude of clinical manifestations,
including bound-down skin, Raynaud's phenomenon,
esophageal dysfunction, pulmonary fibrosis, renal fail-
ure, and cutaneous ulcerations secondary to vascular
insufficiency. The cause of increased collagen deposi-
tion in body tissues in scleroderma remains an enigma.
Recent research has implicated circulating platelet
aggregates and elevated beta-thromboglobulin' as well
as antibodies directed against the endothelial cell.^ This
results in small vessel damage leading to increased de-
position of collagen by fibroblasts.
Raynaud's phenomenon is an arteriolar vasospastic
condition that is often seen in PSS. A variety of medica-
tions have been used to treat Raynaud's phenomenon.
These include oral agents, such as phenoxybenzamine,
alpha-methyldopa, guanethidine, captoprii, and ver-
apamil. Also, intraarterial reserpine, intravenous pros-
tacyclin, topical nitroglycerin, sympathectomy and
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biofeedback have been used.^ Recently, Kahan and his
associates"* reported that the use of oral nifedipine (a
calcium channel blocker) in patients with Raynaud's
phenomenon resulted in a decrease in the mean number
of digital vasospastic attacks from 29.5 to 4.3 per week
concurrent with a subjective improvement in 14 of 16
patients. They also found that nifedipine was effective in
a single-blinded crossover study of four patients.
Raynaud's phenomenon, which involves transient
cutaneous ischemia due to a vasospastic condition, is
somewhat similar to the cutaneous ischemia from
microvascular disease, which occurs in ulcers of
scleroderma. Therefore, this report prompted us to use
nifedipine in treating a cutaneous ulcer that was unre-
sponsive to conservative therapy in a patient with PSS.
Case Report
A 68-year-old white woman wa's seen in consultation at the
Department of Dermatology, University of Michigan with a
3-year history of an ulcer on the medial aspect of her lett toot.
The etiology ot the ulcer was uncertain. She had a 15-year
history of PSS with Raynaud's phenomenon, dysphagia, and
cutaneous sclerosis. Two years prior to her presentation, an
angicgraphy of the left leg had revealed an arterial blockage. In
an etfortto increase blood supply to the foot, she subsequently
had a therapeuticleft femoral popliteal bypass in lanuary 1981
and a left lumbar sympathectomy in October 1981, but the
ulcer persisted. She was first seen at the University of Michigan
in February 1982, and extensive inpatient and outpatient
treatment with bedrest, whirlpool, topical benzoy! peroxide,
and systemic antibiotics were tried with little success over a
period of 8 months.
She was in no acute distress. Physical findings included a 3
X 3-cm, purulent, shallow ulcer with discrete margins located
superior and anterior to the left medial malleolus (Fig. 1). Al-
though the left leg had a femoral pulse, the popliteal, posterior
tibial, and dorsalis pedis pulses were undetectable. The left
foot was also cold to touch. The skin of the hands, feet, and
ankles was very taut. There were periungual telangiectasias
on the fingers and sclerodactyly. She had a beaked nose and
radial furrowing around the mouth with bound-down facial
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FIG, 1, Appearance of the ulcer at the end of one month therapy
with nifedipine. Note outline of previous ulceration.
FIG, 2. Appearance of the ulceration after ihree months oi
nifedipine. Note the total reepilhelialization ofthe ulcer.
skin. Similarly, the rest of her skin was sclerotic and hound-
down.
Pertinent laboratory findings revealed an elevated Wester-
gren erythrocyte sedimentation rate of 100, Systemic manifes-
tations of PSS included findings consistent with moderate
pulmonary fibrosis as demonstrated by a reduced functional
vital capacity of 1.95 L, forced expiratory volume at 1 second
of 1,34 L, and an abnormal carbon monoxide diffusion of 8.72.
The upper gastrointestinal series revealed decreased
esophageal motility of the distal esophagus consistent with
PSS, An x-ray of the left ankle failed to reveal any os-
teomyelitis. Cultures ol the ulcer grew Pseudomonas
aeruginosa (sensitive to sulfamethoxazole-trimethoprim) and
coagulase positive staphylococcus (sensitive to erythromycini,
Antinuclear, anticentromere, Scl-70 (scleroderma antibody)
and anti-nDNA antibodies were negative. Chest x-ray was
within normal limits. The rest of the laboratory evaluation was
unremarkable.
Local treatment to the ulcer was instituted and consisted of
daily whirlpool and Op-Site dressings. She also received a
10-day course of erythromycin base (500 mg four times daily)
and sulfamethoxazole 400 mg/trimethoprim 80 mg (two tab-
lets four times daily). No evidence of healing occurred during
the course of antibiotic therapy despite adequate wound care.
The patient was then given a trial of oral nifedipine at 10 mg
three times daily. This was slowly increased over a period of 7
days to 40 mg three times daily. Her only side effect was
dizziness (due to slight postural hypotension). Within 2 weeks,
the foot became pinker in color and warm to touch. Over the
course of 1 month, the ulcer became filled with granulation
tissue and had totally reepithelialized approximately three-
quarters of its surface (Fig. I), At this time, she was discharged
on nifedipme 10 mg three times daily (to avoid orthostatic
hypotension), Op-Site, and home whirlpool. Follow up 2
months later revealed continual improvement with only a
2-mm area of healing tissue (Fig. 2). The slower healing was
possibly due to the reduced nifedipine dosage. There was no
improvement in the PSS itself.
Comment
The dramatic resolution of the ulceration of 3 years
duration in this patient suggests that nifedipine may be a
useful therapeutic agent in the therapy of ulcers in pa-
tients with scleroderma. Refractory digital and elbow
ulcerations in a patient with severe Raynaud's
phenomenon and PSS have been reported to respond to
nifedipine.-'̂  Nifedipine is a calcium channel blocker that
functions by impairing transfer of calcium into the cell,
resulting in a lower intracellular concentration of cal-
cium.** The net effect is a relaxation in the smooth mus-
cle beds of the body. The vascular smooth muscles of the
arteriolar bed are far more sensitive to the action of
nifedipine that those associated with the venous bed.
The net effect is increased arteriolar pressure with a con-
current increase in capillary pressure and an enhanced
cutaneous blood flow. This improvement in cutaneous
circulation following use of nifedipine has been
documented both in vitro'' and in vivo.^ Of all the cal-
cium channel blockers now commercially available for
patient use, nifedipine is the most potent cutaneous
vasodilator.
Nifedipine is rapidly absorbed when taken orally and
reaches its peak serum concentration in 20-45 minutes,
with a half-life of 2.5-3 hours. The intact drug is QĈ r
bound to plasma proteins, whereas the free acid metabo-
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lite is only S49c bound. Over 9Q^/c of the orally adminis-
tered dose of nifedipine is excreted by the kidney in the
first 24 hours.** Adverse side effects are uncommon, but
include palpitations, orthostatic hypotension, reflex
tachycardia, dizziness, a nonspecific rash (erythematous
pedal edema), and flushing.'"
Our patient had PSS with a persistant ankle ulcer for
many years. The etiology of the ulcer in this patient is
unclear. It may have been due to microvascular disease,
as seen in scleroderma, or to arterial occlusion. Attempts
to treat the ulcer with conventional inpatient and outpa-
tient therapy were unsuccessful; however, nifedipine in
doses of 120 mg daily proved efficacious. The optimal
dosage for ischemic sclerodermatous ulcerations is un-
known at this time. Reports indicate that nifedipine in
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